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Background: Canine leishmaniosis (CanL) caused by Leishmania infantum is a widespread endemic disease in SW
Europe. This study was designed to determine how veterinarians clinically manage CanL in this region by analysing
information collected in a questionnaire completed by local veterinarians working in clinics in France, Portugal,
Greece, Spain, Italy and Slovenia.
Methods: Over the period 2004–2011, a questionnaire on CanL was sent to 12,546 small animal clinics located in
the six countries surveyed. The questionnaire with 10 items comprising open and closed questions sought to
obtain comparable data regarding the main clinical manifestations of CanL, the diagnostic methods used, the
treatment regimens selected, recommended preventive measures and awareness of the important public health
implications of CanL.
Results: The data collected reflect similarities in the clinical manifestations reported although there was some
variation in the concurrent diseases described, and wide variation in the clinical management of CanL among the
countries examined in terms of dosing regimens, therapeutic agents and the criteria used to diagnose CanL. Most
veterinarians properly informed dog owners about the preventive measures available and about the zoonotic
implications of CanL.
Conclusions: This survey describes the current situation in SW endemic countries in Europe regarding the clinical
management of CanL. The data collected reveal a need to unify criteria from evidence-based medicine to determine
and similarly apply the best diagnostic and treatment methods available for this disease in the different countries.
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Leishmaniosis is a disease caused by several species of
protozoan parasites of the genus Leishmania Ross, 1903
[1,2]. It is transmitted to humans and animals by blood-
feeding female phlebotomine sand flies [3,4]. Leishmania
infantum causes a severe zoonotic disease in dogs and
humans [5], the domestic dog being considered the main
reservoir for human infection by this species [6,7]. Due
to the zoonotic nature of the disease, dogs infected with
L. infantum are a serious concern for both animal and* Correspondence: gmiro@ucm.es
6Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad
Complutense de Madrid, Avda. Puerta de Hierro s/n, 28040 Madrid, Spain
Full list of author information is available at the end of the article
© 2014 Bourdeau et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.public health [8]. The high incidence of canine leishma-
niosis (CanL) in SW Europe is well known [5] and it has
been estimated that at least 2.5 million dogs could be in-
fected (16.7%) [9]. The disease also seems to be spread-
ing from the Mediterranean basin into northern Europe
[10,11]. This northward spread has been attributed to
climate change and globalisation (mainly the movement
of dogs between countries) in the past decade [12].
These factors could have led to new disease foci in the
north of classic endemic regions throughout Europe
such as the foothills of the Alps [13] and the Pyrenees
[14]. Moreover, there have been recent outbreaks of
human leishmaniosis in classic endemic regions like
Madrid, Spain [15,16].ral Ltd. This is an Open Access article distributed under the terms of the Creative
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siderably higher than the rate of apparent clinical disease
[17]. Clinical CanL is a chronic systemic disease charac-
terized by a variable and nonspecific spectrum of signs
of different severity determined by the host immune re-
sponse [8,18]. To describe the wide variety of clinical
manifestations of CanL and provide a tool to determine
the best treatment options and prognosis, a classification
scheme defining four clinical stages based on clinical
signs, clinicopathological abnormalities and serological
status has been proposed by the LeishVet group [19].
According to this scheme, the main clinical signs of
CanL are one or more of the following: weight loss,
lethargy, muscular atrophy, non-regenerative anaemia,
generalized lymphadenomegaly, splenomegaly, renal dis-
orders, ocular lesions, arthropathies, onycogryphosis and
skin lesions [8,19]. This broad spectrum of clinical signs
means that the list for a differential diagnosis of CanL is
extensive [19,20] and an integrated approach is needed
to correctly diagnose the disease. This approach must be
based on the following information: epidemiological
data, clinical examination, complete blood count (CBC),
biochemical profile, urinalysis, quantitative serological
techniques and microscopy observation of Leishmania
amastigotes in target tissues (lymph nodes, skin, and/or
bone marrow) [21]. Currently available antileishmania
drugs improve clinical signs after treatment, but para-
sitological cure is not attained [22-25]. The clinical re-
sponse to treatment can vary depending on the initial
clinical status and the specific response to therapy of
each animal [19]. Combinations of meglumine antimoni-
ate or miltefosine with allopurinol (a leishmaniostatic
agent) have been widely used and considered first line
treatment against CanL since they are the most effective
[19,26-28]. Other drugs have been also used such as
amphotericin B, aminosidine, pentamidine, metronidazole
and spiramycin combined, enrofloxacin, marbofloxacin,
ketoconazole and oleylphosphocholine with variable effi-
cacy [18,23,29]. More recently, the immunomodulator
domperidone has been approved for veterinary use and
could be useful to treat non-severe clinical cases [30].
According to the results of both laboratory and field
studies [31-35], the best way to reduce the spread of
L. infantum infection in endemic areas is to protect dogs
with topical insecticides [18,36]. Topical formulations
against sand flies on dogs are usually spot-on or collar
form products. The efficacy of several repellents applied
to dogs has been recently reviewed [36].
In addition, several vaccine candidates against CanL
infection have been recently tested [36-38]. In Europe,
a vaccine based on the secreted-excreted antigen of
L. infantum (CaniLeish, Virbac Animal Health) has been
recently licensed [39], and has been available in some
European countries since 2011. It is claimed that theCaniLeish vaccine induces cell-mediated immunity, pro-
moting a Th1 response [40,41]. However, large-scale
field studies are needed to determine if this vaccine will
help control CanL in Europe.
To date, our understanding of CanL infection in Europe
has been limited by a lack of comparable field data. More-
over, many clinical studies have used different approaches,
sometimes very specialized, that do not really reflect the
field situation.
This paper describes a survey conducted to assess the
current situation of CanL in SW Europe based on a
standardized questionnaire administered to local veteri-
narians with clinics in six countries: France, Portugal,
Greece, Spain, Italy and Slovenia. Our survey provides
important information concerning the clinical aspects
and management of CanL in this region of Europe.
Methods
A questionnaire to obtain information on CanL was ini-
tially created and tested in France, and then validated by
academics from renowned European Veterinary Schools.
The items included were based on the experience and
results of a previous study [42]. The questionnaire was
translated to each of the languages of the countries in-
cluded in the study and sent to 12,546 small animal
clinics successively in the six countries over the period
2004–2011. To avoid duplication of data, one question-
naire was sent per practice.
The questionnaire was designed to obtain the follow-
ing data: the number of dogs examined per year at the
clinic, the number of cases of CanL diagnosed in the
past year, the frequency and main clinical signs of CanL
detected, the frequency of concurrent diseases, the diag-
nostic method of choice, the treatment regimen used,
survival times of animals after treatment, preventive
measures recommended and the veterinarian’s opinion
about the use of effective vaccines and public health
implications.
Results
Reply rate, veterinary clinic clientele and frequency of
CanL cases
Of 12,546 questionnaires initially sent, 2099 were com-
pleted and returned to give an overall reply rate of 16.7%.
Reply rates for the six countries in descending order were:
Slovenia 46.7% (49/105), France 17.9% (994/5567), Portugal
17.8% (141/790), Greece 17.6% (201/1144), Spain 16.1%
(483/3000) and Italy 11.3% (231/2040). In France, 30.1% of
replies were issued from the endemic part of the country
and 69.9% from the non endemic area (eg, the participation
of veterinary clinics in France from endemic areas was 14.3
to 42.9% and in the non endemic areas from 3 to 33%).
The first part of the questionnaire was designed to
characterize the clientele of the different practices. The
Table 1 Number of dogs admitted at least once per year to the veterinary clinics
Number of clients (%) France Greece Italy Slovenia Spain Portugal
<1000 22.1 64.8 62.1 59.2 36.1 65
1000-2500 40.1 28.1 31.7 20.4 35.1 27
2500-5000 29.3 7.1 6.1 10.2 26.6 6
>5000 8.5 0 0 0 2.1 2
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least once”. There were four response categories for this
question: <1000 (under 19 dogs per week); 1000–2500
(19 to 48 dogs per week); 2500–5000 (48 to 96 dogs per
week) and >5000 dogs (more than 96 dogs per week)
(Table 1). France and Spain have mainly medium and
medium-large sized clinics (69.4% and 61.7% respect-
ively). Large veterinary hospitals admitting more than
5000 dogs per year are only found in France (8.5%),
Spain (2.1%) and Portugal (2%). Italy, Greece, Portugal
and Slovenia have mostly small and medium sized clinics
(93.8%, 92.9%, 92% and 79.6% respectively).
We asked the clinicians to provide an average number
of CanL cases per year calculating the mean of the last
two years. The total number of CanL cases includes
newly diagnosed cases. As indicated in Table 2, three
countries in endemic areas for CanL reported a higher
incidence of CanL: Greece, Spain and Portugal. Al-
though Italy is also a CanL endemic country, unfortu-
nately the information on this issue was missing. France
has both endemic and non-endemic areas. The CanL
cases in France were thus divided into those reported by
veterinarians whose practices were in endemic and non-
endemic areas. For Slovenia, very few positive CanL
cases, mostly imported, were reported.
Frequency of clinical signs of CanL and concurrent
diseases
Table 3 provides the frequencies of clinical signs of CanL
on which the veterinarians based their suspicion of dis-
ease in each country. Clinical signs were categorized as:
1-early detectable signs; 2- skin lesions; 3- signs related
to immune complex deposition; or 4- unusual signs
(Figure 1). When we looked at the factors mainly consid-
ered for CanL diagnosis, weight loss, alopecia, lym-Table 2 Mean number of dogs with CanL observed on a yearl
CanL cases (%) France a/b Greece
0 46.1 / 8.7 1.5
1-5 29.8 /32.1 15.1
5-10 7.4 / 18 15.6
10-20 6.9 / 17 22.6
20-50 5.6 / 13.9 30.7
>50 4.2 / 10.3 14.5
(a) Veterinarians in general; (b) Veterinarians working in endemic areas; (*) Breederphadenomegaly, lethargy, pale mucosa and some skin
lesions emerged as those most frequently observed,
whereas diarrhoea and fever were less frequently re-
ported. 37% and 39% of veterinarians never observed
fever and diarrhoea, respectively. Renal disease was
widely described and is thought to be of great diagnostic
value. Ocular lesions, epistaxis and arthropathies were
less frequently observed but their presence is of high un-
favourable prognostic value.
An important aspect of this section was to describe
the presence of diseases associated with CanL. As associ-
ated diseases, the clinicians reported vector-borne, para-
sitic or infectious diseases, endocrinopathies, neoplasias,
autoimmune and metabolic diseases. The most frequent
coinfections mentioned were canine ehrlichiosis (51%),
followed by other vector-borne diseases: dirofilariosis
(12%) and babesiosis (6%); parasitic diseases: demodico-
sis (8%) and sarcoptic mange (6%), and infectious dis-
eases: dermatophytosis (4%). It should be noted that the
Greek participants reported the highest incidences of
coinfections with canine ehrlichiosis (86%) and dirofilar-
iosis (22%), and the French clinicians described CanL
mostly associated with demodicosis (14.8%), sarcoptic
mange (14.8%) and dermatophytosis (8.7%).Diagnostic methods
When leishmaniosis was suspected, specific tests were
employed to confirm a diagnosis of CanL. The diagnos-
tic methods asked about were classified into: cytology
and microscopic examination (skin lesions, lymph nodes
or bone marrow), serological tests (IFAT, ELISA and
rapid tests) or other techniques (PCR, histopathology,
immunohistochemistry and protein electrophoresis)
(Table 4).y basis in the veterinary clinics
Italy Slovenia Spain Portugal
nd 73.5 5.1 7.1
nd 12.2 24.9 27
nd 0 14.7 10
nd 2* 21.3 19
nd 0 21.1 21
nd 0 12.7 16
with 50 Basset Hounds originally from Italy; nd: not determined.
Table 3 Percentages of clinical signs on which veterinarians based their suspicion of CanL
France n = 994 Greece n = 201 Italy n = 231
Clinical signs % Never Occasional to
frequent
Always Never Occasional to
frequent
Always Never Occasional to
frequent
Always
Weight loss 4.8 74.8 20.4 0.5 73.7 25.8 0.9 80.4 18.7
Alopecia 12.3 78.3 9.4 2.8 92.7 4.5 2.3 86.7 11
Lymphadenomegaly 9.1 70.6 20.3 0.5 70.8 28.6 4.6 71.2 24.2
Lethargy 13.2 78 8.8 4 88.4 7.5 5.1 87 7.9
Pale mucosa 21.3 73.2 9.4 1.1 87 12 4.2 88.8 7
Exfoliative dermatitis 21.6 35.8 6.8 4.8 91.1 4.1 1.9 87.6 10.5
Onychogryphosis 14.1 77.8 8 5 90 5 6.8 83.1 10
Skin ulcers 22.7 72.9 4.4 5.5 89 5.5 4.7 12.3 83
Pyodermatitis 21 73.3 5.7 12.5 86.9 0.6 0.5 11.7 87.8
Footpad lesions 20.1 76.9 3 19.6 80.4 0 12.7 85.4 1.9
Cutaneous
depigmentation
49.8 48.7 1.5 34 66 0 33 64.6 2.4
Cutaneous nodules 48.9 48.2 2.9 46.1 53.9 0 27.6 69 3.4
Renal disease 16.2 79.1 4.7 2.8 97.2 0 4.1 90 5.9
Ocular lesions 25.8 71.1 3 5.5 89.5 5 18.2 0 81.8
Epistaxis 30.1 68.2 1.6 7.5 91.9 0.5 40 6.7 53.3
Arthropathies 42.5 56.3 1.3 16 83.4 0.6 59.2 40.3 0.5
Fever 38.6 58.6 2.9 41.4 58.6 0 35.9 63.2 1
Diarrhoea 58.1 40.9 0.9 33.5 66.5 0 38 60.2 1.9
Slovenia n = 49 Spain n = 483 Portugal n = 141
Weight loss 0 81.8 18.2 3.1 70.8 26.1 1.4 66.2 26.6
Alopecia 0 100 0 1.6 85.9 12.5 1.4 80.6 10.1
Lymphadenomegaly 0 100 0 13.0 61.3 25.7 2.9 69.8 18.0
Lethargy 0 81.8 18.2 3 90.4 6.7 5.8 77.0 3.6
Pale mucosa 0 90 10 4.3 87.7 8 6.5 76.3 4.3
Exfoliative dermatitis 9.1 90.9 0 2.8 82.8 14.4 3.6 77.0 6.5
Onychogryphosis 0 100 0 5.7 85.8 8.5 3.6 81.3 5.8
Skin ulcers 0 100 0 5.5 88 6.4 7.2 79.9 2.2
Pyodermatitis 0 90.9 9.1 7.3 86.7 6.1 8.6 78.4 0.7
Footpad lesions 0 100 0 13.2 84.2 2.6 10.8 76.3 1.4
Cutaneous
depigmentation
0 100 0 21.9 75.4 2.7 2.9 53.2 3.6
Cutaneous nodules 0 100 0 23.8 73.7 2.5 20.1 48.9 15.8
Renal disease 0 100 0 7 89.1 4 3.6 85.6 1.4
Ocular lesions 0 90 10.0 7.9 87.1 4.9 10.1 77.7 1.4
Epistaxis 11.1 88.9 0 8.2 73 18.8 8.6 79.1 0.0
Arthropathies 0 100 0 13.2 84.9 1.9 21.6 64.7 0.7
Fever 0 90.9 9.1 38.7 60.5 0.7 32.4 54.0 0.0
Diarrhoea 0 90.9 9.1 30.2 69.3 0.5 33.1 51.8 0.0
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lymph node aspirates as their first choice etiological
diagnostic method (Figure 2). Cytology samples obtained
from bone marrow and skin lesions showed goodacceptance but were less used. Veterinarians who would
never use an invasive technique for a bone marrow cy-
tology were predominant in France (65.5%), Greece
(69.6%) and Italy (59.9%) and those who never examined
Figure 1 Frequencies of the clinical signs of CanL reported by veterinarians from Italy, Portugal, Spain, Greece and France.
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France (65%). As illustrated in Figure 2, an in-house
etiological diagnosis consisting of microscopy observa-
tion of potentially infected tissue was not of routine use.
Accordingly, a minority of veterinarians reported they
always used a cytological method: lymph nodes (10%),
bone marrow (7%) and skin lesions (6%). As comple-
mentary tests, microscopy observation of lymph node
aspirates was the most used occasionally to frequently
(62%). The quantitative serological method most used
was IFAT (82.7%), followed by qualitative in-house rapid
tests (78.2%) and ELISA (72.2%). For routine use, IFAT
and qualitative rapid tests were described as always
employed by 43% and 37% of veterinarians respectively
(Figure 3). Qualitative rapid tests were most used for a
routine diagnosis in Greece (58.3%), Portugal (63.5%),
Spain (34.5%) and Italy (30.9%). Lastly, among the
“Other techniques”, PCR was most reported (61%). Pro-
tein electrophoresis (14%) and immunohistochemistry
(13%) were used more in routine practice than PCR (6%)
or histopathology (1%) (Figure 4).
Treatment and follow-up of CanL
For this section of the questionnaire, we report and
summarize the therapeutic regimens and agents selected
by the veterinarians. The agents proposed were: antimo-
nials, allopurinol, amphotericin B, pentamidine, ketoco-nazole, metronidazole and fluoroquinolones. Those most
used were antimonials and allopurinol, the latter being
the most frequently used (Figure 5).
The regimens included in the questionnaire were: anti-
monials plus allopurinol, allopurinol alone, antimonials
alone and amphotericin B (Table 5). Most vets in en-
demic countries used mostly the combination antimo-
nials and allopurinol to treat CanL, except for Greece
and Portugal where allopurinol alone was the first treat-
ment option. Allopurinol alone was chosen as first line
treatment by the Portuguese, Greek and Slovenian clini-
cians. Despite their lower efficacy, antimonials alone
were the treatment of choice for 13.7% to 17.5% depend-
ing on the country, and were used as second line treat-
ment by the Spanish and Italian vets. The use of
amphotericin B was not an option for the European
practitioners (0.4-3.1%).
Survival times of treated animals were longer in Spain,
Portugal, Italy and France. In Greece, the expected time
of survival was shorter. The data from Slovenia was
insufficient to draw any conclusions on this point
(Table 6).
Preventive measures and public health implications
In this section of the questionnaire, the veterinarians
were asked about their recommendations to dog owners
about the use of topical insecticides if the dogs were
Table 4 Diagnostic tools used by veterinarians to confirm a suspected case of CanL
France n = 994 Greece n = 201 Italy n = 231
Technique % Never Occasional to
frequent
Always Never Occasional to
frequent




Lymph nodes 34.6 52.8 12.6 21.4 58.6 20 46.7 48.0 5.3
Bone Marrow 65.5 30.6 3.9 69.6 29.4 1.1 59.9 33.6 6.6
Skin lesions 65 28.9 6.1 56.6 40.4 3 28.8 56.5 14.7
Serology
IFAT 22.7 28.7 48.6 16 45 39 4.3 48.9 46.8
Rapid tests 42 33.9 24 4.6 37.1 58.3 30.9 38.2 30.9
ELISA 13.5 34.7 51.9 14.3 58.9 26.8 25.2 37.7 37.1
Other techniques
PCR 55.7 36.6 7.7 52.1 46.4 1.4 20.9 66.9 12.2
Protein
electrophoresis
42.3 41 16.8 76.6 20.4 2.1 10.6 39.8 49.7
Histopathology 51.1 45.8 3.1 72.3 27.7 0 64.9 35.1 0
Immunohistochemistry 94.3 4.7 1 94.5 5.5 0 83 13.8 3.2
Slovenia n = 49 Spain n = 483 Portugal n = 141
Cytology
Lymph nodes 2 4 0 14.3 80.2 5.5 19.4 72.1 8.6
Bone Marrow 2 2 0 18.1 71.4 10.5 36.2 53.2 10.6
Skin lesions 6.1 2 0 34.2 61.8 3.9 82.9 14.6 2.4
Serology
IFAT 0 4 0 6.3 37.9 55.9 9.4 36.7 25.9
Rapid test 0 2 2 11.5 54.0 34.5 20 43.5 36.5
ELISA 0 2 6.1 42.3 47.3 10.4 43.9 43.9 12.2
Other techniques
PCR 0 2 2 8.3 86.6 5.1 57.8 37.6 4.7
Protein
electrophoresis
0 2 0 nd Nd nd 96.5 1.8 1.8
Histopathology 0 4.1 0 35.3 63.9 0.8 91.5 6.8 1.7
Immunohistochemistry 0 2 0 15.0 40.4 44.6 33.8 48.8 17.5
nd: not determined.
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ians were also asked about other prophylactic measures
they recommended for dogs living in endemic areas:
keeping indoors at night, the use of fine-mesh nets and/
or environmental insecticides.
The replies given to the questions in the prophylaxis
section are provided in Table 7. Most vets recommended
the use of insecticides and repellents to prevent the
spread of CanL for a dog living in an endemic area
(91.6%) or moving to an endemic area (83.7%). The most
recommended preventive measure by vets was that dogs
should be kept indoors at night (45.4%) followed closely
by the use of fine-mesh nets (31.7%).
Most vets questioned stated they would use an effect-
ive and safe vaccine, if available, in dogs living in en-
demic areas (96.9%) and dogs travelling to an endemicarea (96.2%), even combined with other prophylactic
measures (89.9%) (Table 7).
Most clinics informed their clientele about the public
health implications of CanL (77.3%). The southern
European inhabitants were sufficiently informed about
this topic (78.3%). In the case of Portugal, these figures
were only 63% and 40% respectively. Very few vets were
aware of the possibility of simultaneous dog-owner in-
fection (6.6%).
Discussion
The questionnaire used in our survey was designed to obtain
data about the current situation of CanL in SW European
countries. This is the first multinational approach to the
collection of field data and comparative information on
CanL. Data collected from similar questionnaires have
Figure 2 Cytology options used to diagnose CanL reported by veterinarians from Italy, Portugal, Spain, Greece and France.
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tion and management of CanL [43-46].
The size of a veterinary clinic and number of em-
ployees reflects the quality of service provided [47].
Hence, the presence of many small clinics and practices
in Italy, Greece, Portugal and Slovenia with limited
resources indicates a more basic veterinary service pro-
vided by professional veterinarians. In contrast, countries
like France and Spain have a large number of well-
equipped veterinary clinics and centres, determining a
quantitative improvement in the degree of specialization.
The presence of larger veterinary clinics is an indicator
of specialization and of a wider knowledge of the corre-
sponding staff. France emerged as the country with the
larger proportion of veterinary hospitals involved in
completing the questionnaire.
The issues discussed hereafter relate to the informa-
tion provided by all the questionnaires except thosecompleted by the Slovenian vets. The reason for this is
the scarce knowledge of CanL in this country and the
limited number of reported cases, which suggests a need
for further studies in non-endemic areas to evaluate the
potential risk of developing this disease [48].
According to the average numbers of CanL cases per
year reported for each country, the well known endemic
areas Greece, Italy, Portugal, Spain and southern France
emerged as leishmaniosis hot spots [10].
The broad spectrum of clinical signs of CanL hinder
and lengthen the process of its clinical diagnosis [18]. In
endemic areas, a single sign compatible with CanL
should justify confirmation of the infection [17]. In this
survey, the most common clinical signs reported were:
weight loss, alopecia, lymphadenomegaly, lethargy, pale
mucosa, renal disease and a large number of skin le-
sions. These are all strong clinical indicators of CanL as
widely reported in the scientific literature [8,19,49] and
Figure 3 Serology techniques used to diagnose CanL reported by veterinarians from Italy, Portugal, Spain, Greece and France.
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we called “early detectable signs” were the most import-
ant indicators of the presence of the disease in terms of
their high frequency and diagnostic value. Weight loss,
alopecia and lymphadenomegaly have been frequently
observed in an objective and thorough physical examin-
ation of the dogs [50-53]. Nevertheless, the factors
lethargy or pale mucosa, which is caused by a non-
regenerative anaemia, are not so definitive for diagnos-
ing the disease since they are subjective and transient,
respectively [54,55]. Cutaneous lesions were often ob-
served but are not specific to CanL and may be caused
by many other diseases such as autoimmune diseases.
Clinical signs of high prognostic value are those associ-
ated with immunocomplex deposition at the renal glom-
eruli [56], joints [57], eyes [58-60] or blood vessels [61].
These signs are a severe manifestation of disease pro-
gression, renal disease being the more frequently re-
ported severe form [62] and the first cause of death in
dogs with CanL. Fever and diarrhoea are unspecific, un-
common and were described as incompatible with CanL
by the responding practitioners. Fever may indicate the
presence of another infectious disease (mainly vector-borne), autoimmune disease or a toxic event. Diarrhoea
is also caused by gastrointestinal parasites, inflammatory
disease, food allergy or a gastrointestinal disorder. Diar-
rhoea is an infrequently observed clinical sign of CanL
and has only been reported in cases of ulcerative colitis
[63,64].
The management of CanL should include a differential
diagnosis to rule out other vector-borne diseases (eg, ehr-
lichiosis, babesiosis) or diseases producing skin lesions
(eg, autoimmune diseases) [18]. Veterinarians should also
keep in mind that many dogs with CanL could have con-
comitant disorders linked to their immunocompromised
state or due to another vector-borne disease [65,66]. In
the present survey, the disease most frequently associated
with CanL was canine ehrlichiosis, and this was followed
by many other parasites (eg, dirofilariosis, babesiosis,
demodicosis) or infectious (eg, bacterial dermatoses, der
matophytosis) diseases [67]. The presence of other canine
vector-borne diseases is directly related to the vector dis-
tribution in southern European countries. It should never-
theless be considered that some vector borne diseases
like Bartonella spp. or Anaplasma spp. infection are
still underdiagnosed and that affected animals could be
Figure 4 Other techniques used to diagnose CanL reported by veterinarians from Italy, Portugal, Spain, Greece and France.
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vided the higher number of coinfections with canine ehr-
lichiosis and dirofilariosis. This may be attributed to the
high endemicity of these diseases due to appropriate cli-
mate conditions in this country. In France, cases of CanL
were more associated with demodicosis, sarcoptic mange
and dermatophytosis, probably due to the traditional ex-
pertise of French veterinarians in dermatology. These find-
ings could thus depend on the geographical location of
the country and the interest of the different veterinarians
questioned.
When CanL was suspected, specific tests were employed
to confirm its diagnosis. Observation of stained lymph
node aspirates by microscopy was employed by veterinar-
ians more frequently than observation of samples obtained
from bone marrow aspirates or skin cytologies. As routine
tests, practitioners rarely undertook the microscopic de-
tection of amastigotes in targeted tissues since cytology is
usually more frequently performed by a consulting spe-
cialist. Although the direct observation of the parasite is a
conclusive diagnosis, microscopy shows a low sensitivity
and its specificity depends on parasite load, observer skill
and the time dedicated to examining smears [6,69]. Notsurprisingly, invasive techniques to obtain bone marrow
aspirates was infrequently reported because of the skill re-
quired and the need for sedation, which is time consuming
and costly. In contrast, the scarce use of skin cytology
among the vets questioned is surprising.
Serological tests were widely used by the clinicians.
The diagnostic method most used was IFAT. In addition,
IFAT was the most widely used routine technique. A
reliable diagnosis of CanL requires quantitative sero-
logical methods guided by an exhaustive evaluation
of clinical signs and clinicopathological abnormalities
[18,23]. Quantitative serology is appropriate for diagno-
sis in clinical practice and for treatment follow-up
[18,23,29]. However, it has to be performed in special-
ized laboratories. A high percentage of the vets (37%)
reported the routine use of qualitative rapid tests. Rapid
tests are not able to identify dogs with low antibody
levels so a positive result by a qualitative test is only a
first step and must be followed by a quantitative sero-
logical method. This is recommended in the Leishvet
guidelines [18,19] for precise antibody titration, a good
prognosis and therapy monitoring. In the section “Other
techniques”, PCR was the technique most widely
Figure 5 Active ingredients used by veterinarians to treat confirmed cases of CanL in Italy, Portugal, Spain, Greece and France.
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in specialized laboratories. It is not used alone for diag-
nostic purposes; a positive PCR diagnosis indicates
L. infantum infection but not necessarily clinical disease
in the dog [18]. Real-time PCR is an advanced technique
that can quantify Leishmania loads in infected dog tis-
sues. However, although it is useful for diagnosis and the
follow-up of treated dogs [29,70,71], its results are diffi-
cult to interpret due to their inconsistency such that
very sick dogs may show low parasite loads and vice-Table 5 Therapy protocols used by veterinarians to treat con
Protocol % France Greece
Antimonials + allopurinol 80.8 24.9
Allopurinol only 23.3 31.3
Antimonials only 17.5 16.9
Amphotericin B only 0 1.5
nd: not determined.versa. Under this same section, the reported use of rou-
tine diagnostic tests such as protein electrophoresis and
immunohistochemistry should help improve the diagno-
sis of CanL [21,72].
The antileishmania agents most used by the vets sur-
veyed were antimonials and allopurinol, the latter being
the most frequently employed. The first treatment op-
tion was meglumine antimoniate, which is usually asso-
ciated with allopurinol. These drugs have a synergistic
activity when combined [26,27,73]. Despite the fact thatfirmed CanL cases
Italy Slovenia Spain Portugal
65.4 2 58.6 68
12.1 6.1 8.5 84
13.9 0 13.7 nd
0.4 0 3.1 nd
Table 6 Survival times of dogs after treatment
Survival rate % France Greece Italy Slovenia Spain Portugal
< 3 months 8.6 0.19 9.6 2 0 0
3-6 months 4.7 38.9 11 2 1 1
6 m – 1 year 7.2 48.1 12.5 2 4 3
1-2 years 13.5 25.8 21.5 2 8 10
2-5 years 35.7 8.2 42.8 2 48 58
> 5 years 30.3 7.1 45.1 0 39 38
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recommended owing to a reported increase in clinical
disease recurrence [74]. Amphotericin B was fortunately
not an option for practitioners; it is the first line option
to treat human leishmaniosis and its cumbersome endo-
venous administration route makes it unsuitable for vet-
erinary use. Moreover, this molecule is poorly tolerated
by dogs. It should be noted that when this survey was
conducted, miltefosine, was still not licensed in Europe
and thus none of the clinicians reported its use.
The dosing regimen used to treat CanL differed among
the countries. In France, antimonials were administered
at a dose of 100–200 mg/kg sc (subcutaneously) for
20–30 days combined with allopurinol at a dose of 10–
30 mg/kg po (orally) for several months, or for 7–10 days
per month or even for life. In Spain, antimonials were
administered as 50–100 mg/kg bid (twice a day) (89%),Table 7 Preventive measures recommended by veterinarians
health implications
Preventive m
Question answered France % Greece % Italy %
Yes No Yes No Yes No
1 94.8 5.2 96.9 3.1 98.6 1.4
2 93.6 6.4 95.7 4.3 75.2 24.8
3
3.1 64.1 35.9 57.4 42.6 50.7 49.3
3.2 nd nd 48.9 51.1 41.3 58.7
3.3 4.1 95.9 13.2 86.8 8 92
Vaccina
4 98.7 1.3 90.8 0.0 100 0
5 94 6 93 0.0 100 0
6 92.9 7.1 91.2 8.8 72.6 27.4
Public health i
7 73.6 26.4 98.5 1.5 93.5 6.5
8 88.6 11.4 100 0 96.5 3.5
9 4 96 7.6 92.4 13.7 86.3
Questions: (1) Do you recommend the use of insecticides/repellents for dogs living
repellents for dogs moving to a non endemic area?, (3) Do you recommend any ot
indoors at night, (3.2) Fine-mesh nets, (3.3) Environmental pesticides, (4) Would yo
Would you use an effective and safe vaccine in a dog moving to an endemic area?
prophylactic measures?, (7) Are dog owners aware of the public health implications
CanL?, (9) Are you aware of any cases of simultaneous dog-owner infection?; nd: nocombined with allopurinol at a dose of 20 mg/kg bid for
3–6 months (39%) or 12 months (10%) and even for
life (10%). In Greece, the antimonial dose used was
50–300 mg/kg sc for 20–80 days in combination with allo-
purinol at a dose of 7–40 mg/kg (15 mg/kg of average)
for 6 months. In Portugal, dosing regimes varied from
10–20 mg/kg/sid (once daily) for allopurinol alone or in
association with meglumine antiamoniate at 100 mg/kg/
sid for 1 month. Allopurinol was administered during a
minimum of 3 months to lifelong treatment and was con-
sidered a safe drug. Meglumine antiamoniate side-effects
were occasionally noticed (36%) and included vomiting,
diarrhoea, anorexia, lethargy and pain at the injection site.
All other treatments (amphotericin B, lomidine, ketocona-
zole, metronidazole, antibiotics) were rarely prescribed. In
Italy, antimonials were administered at a dose of 100 mg/
kg bid (71%) sc (63%) combined with allopurinol at a dose
of 10 mg/kg bid for 3–6 months (84%), or for 12 months
(7.5%) and even for life (11%). In Slovenia, the majority of
practitioners used allopurinol alone, while antimonials
were periodically used only in one Slovenian practice. The
rest of the practitioners rarely considered the use of anti-
monials because of their high cost and administration
route. In contrast, allopurinol is cheap and used orally
which is why many Slovenian vets use it on its own. It
should be mentioned that dosing regimens for efficient
agents against CanL vary widely and there are usually overin endemic and non-endemic areas of CanL and public
easures
Slovenia % Spain % Portugal % Total
Yes No Yes No Yes No Yes No
73.5 2 90.1 0 96 4 91.6 2.6
55.1 2 87.5 0.8 95 5 83.7 7.2
Nd nd nd nd 100 0 45.4 21.3
Nd nd nd nd 100 0 31.7 18.3
Nd nd nd nd nd nd 4.2 45.8
tion
Nd nd 100 0 95 5 96.9 1.3
Nd nd 99 1 95 5 96.2 2.4
Nd nd 92.7 0.3 100 0 89.9 8.7
mplications
40.7 8.2 94.6 5.4 63 37 77.3 14.2
46.9 6.1 97.8 2.2 40 60 78.3 13.9
0 61.2 14.3 85.7 0 100 6.6 86.9
in an endemic area?, (2) Do you recommend the use of insecticides/
her prophylactic measures for dogs in an endemic area?, (3.1) Keeping dogs
u use an effective and safe vaccine for dogs living in an endemic area?, (5)
, (6) Would you use an effective and safe vaccine in combination with other
of CanL?, (8) Do you inform owners about the public health implications of
t determined.
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antimonials plus allopurinol = 17 and allopurinol = 13; Italy
antimonials plus allopurinol = 26 and allopurinol = 11).
This situation suggests a need to standardize both the
choice of the most appropriate drug and its dosing
regimen. Surprisingly, the doses of agents used to treat
CanL reported by a few veterinarians were three times
the standard recommended dose. In an effort to
standardize the wide variety of agents and protocols
used in Europe, the LeishVet group has established a set
of guidelines detailing the most effective doses and
drugs against CanL according to evidence based medi-
cine [18,19].
The survival rates provided by the vets must be inter-
preted as self-perceived rates. Notwithstanding, survival
times are getting longer [75] due to improved clinical
management and to new preventive tools such as topical
repellents, vaccines or immunomodulators. Expected
survival is 2–5 years after primodiagnosis, except for
chronic patients with signs of associated immunocom-
plex deposition [76].
Finally, the veterinarians properly informed dog owners
about the preventive measures available and about the
zoonotic implications of CanL. Almost all veterinarians ac-
tively recommended the topical use of insecticides/repel-
lents as reported in other European countries [43-46,77].
Avoiding sand fly bites is useful in preventing L. infantum
infection in dogs and could reduce the incidence of the
disease [34,78].
The veterinarians were also asked about other prophy-
lactic measures they would recommend for dogs in en-
demic areas: keeping dogs indoors at night or the use of
fine-mesh nets and/or environmental insecticides. The
most recommended preventive measure was that dogs
should be kept indoors at night. Spending the night out-
doors has been described as a risk factor for infection by
L. infantum because dogs are exposed to sand flies for a
longer time period [79,80]. The use of fine-mesh nets is
an effective strategy against sand fly exposure [81]. Most
vets recommended the use of an effective and safe
vaccine for dogs in endemic areas (97.4%), moving to
an endemic area (96.5%) or even combined with other
prophylactic measures (94.2%). Used in combination
with topical repellents, vaccination is a promising tool
for controlling CanL [36]. Veterinarians should always
insist on informing dog owners of the health implica-
tions of CanL in their country. It should be mentioned
that health education and knowledge of the disease in
Portugal was the poorest among the countries examined
where CanL is endemic.
In summary, this paper provides a global picture of
the current situation of the clinical management of CanL
in six SW European countries based on data reported by
local veterinarians from each region.Conclusions
This survey collates data on the current situation regard-
ing the clinical management of CanL in SW European
countries. The highly variable data provided by veteri-
narians from each country suggest a need to follow stan-
dardized guidelines indicating the best diagnostic and
treatment options for this disease.
Competing interests
The authors declare no competing interests.
Authors’ contributions
PB designed and distributed the prototype questionnaire to academics from
European Veterinary Schools of the six countries included in the study,
reviewed the first version of the manuscript and finalized the manuscript.
GM compiled the data from the six countries involved, constructed the
tables, drafted and reviewed the first version of the manuscript and finalized
the manuscript. RG constructed the figures, drafted the first version of the
manuscript and finalized the manuscript. GM distributed the questionnaire
to Spanish veterinarians, translated it into Spanish and prepared the
country’s results report. MS and AK distributed the questionnaire to Greek
veterinarians, translated it into Greek and prepared the country’s results
report. AO and IPF distributed the questionnaire to Portuguese veterinarians,
translated it into Portuguese and prepared the country’s results report. GO
and VM distributed the questionnaire to Italian veterinarians, translated it
into Italian and prepared the country’s results report. TK distributed the
questionnaire to Slovenian veterinarians, translated it into Slovenian and
prepared the country’s results report. All authors reviewed the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
The authors are indebted to the numerous practitioners involved in this
survey without whom this study would not have been possible.
Publication of the CVBD9 thematic series has been sponsored by Bayer
HealthCare - Animal Health division.
Author details
1Ecole Vétérinaire de Nantes, Oniris, Université de Nantes, Atlanpole, La
Chantrerie, BP 40706 Nantes, France. 2Clinic of Medicine, Faculty of Veterinary
Medicine, University of Thessaly, Karditsa 43100, Greece. 3Faculdade de
Medicina Veterinária, Universidade Lusofona de Humanidades e Tecnologias,
Campo Grande, 1729-024 Lisboa, Portugal. 4School of Veterinary Clinical
Sciences, University Federico II, Via Federico Delpino 1, 80137 Naples, Italy.
5Small Animal Clinic, Veterinary Faculty of Ljubljana, C. v Mestni log 47, 1000
Ljubljana, Slovenia. 6Departamento de Sanidad Animal, Facultad de
Veterinaria, Universidad Complutense de Madrid, Avda. Puerta de Hierro s/n,
28040 Madrid, Spain. 7Companion Animal Clinic, Faculty of Veterinary
Medicine, Aristotle University of Thessaloniki, Thessaloniki 54627, Greece.
8Faculdade de Medicina Veterinária, Pólo Universitário Alto da Ajuda,
Universidade de Lisboa, Lisboa 1300-477, Portugal.
Received: 17 January 2014 Accepted: 14 March 2014
Published: 24 March 2014
References
1. Ashford RW: The leishmaniases as emerging and reemerging zoonoses.
Int J Parasitol 2000, 30:1269–1281.
2. Desjeux P: Leishmaniasis: current situation and new perspectives.
Comp Immunol Microbiol Infect Dis 2004, 27:305–318.
3. Killick-Kendrick R: Phlebotomine vectors of the leishmaniases: a review.
Med Vet Entomol 1990, 4:1–24.
4. Ready PD: Biology of phlebotomine sand flies as vectors of disease
agents. Annu Rev Entomol 2013, 58:227–250.
5. Dujardin JC, Campino L, Cañavate C, Dedet JP, Gradoni L, Soteriadou K,
Mazeris A, Ozbel Y, Boelaert M: Spread of vector-borne diseases and
neglect of Leishmaniasis, Europe. Emerg Infect Dis 2008, 14:1013–1018.
6. Alvar J, Cañavate C, Molina R, Moreno J, Nieto J: Canine leishmaniasis.
Adv Parasitol 2004, 57:1–88.
Bourdeau et al. Parasites & Vectors 2014, 7:110 Page 13 of 14
http://www.parasitesandvectors.com/content/7/1/1107. Gramiccia M, Gradoni L: The current status of zoonotic leishmaniases and
approaches to disease control. Int J Parasitol 2005, 35:1169–1180.
8. Baneth G, Aroch I: Canine leishmaniasis: a diagnostic and clinical
challenge. Vet J 2008, 175:14–15.
9. Moreno J, Alvar J: Canine leishmaniasis: epidemiological risk and the
experimental model. Trends Parasitol 2002, 18:399–405.
10. Ready PD: Leishmaniasis emergence in Europe. Euro Surveill 2010,
15:19505.
11. Antoniou M, Gramiccia M, Molina R, Dvorak V, Volf P: The role of indigenous
phlebotomine sandflies and mammals in the spreading of leishmaniasis
agents in the Mediterranean region. Euro Surveill 2013, 18:20540.
12. Impact of pet travel on animal and public health. Vet Rec 2008,
162(14):429–430. PMID: 18494172 [PubMed - indexed for MEDLINE].
13. Maroli M, Rossi L, Baldelli R, Capelli G, Ferroglio E, Genchi C, Gramiccia M,
Mortarino M, Pietrobelli M, Gradoni L: The northward spread of leishmaniasis in
Italy: evidence from retrospective and ongoing studies on the canine
reservoir and phlebotomine vectors. Trop Med Int Health 2008, 13:256–264.
14. Dereure J, Vanwambeke SO, Male P, Martinez S, Pratlong F, Balard Y, Dedet
JP: The potential effects of global warming on changes in canine
leishmaniasis in a focus outside the classical area of the disease in
southern France. Vector Borne Zoonotic Dis 2009, 9:687–694.
15. Carrillo E, Moreno J, Cruz I: What is responsible for a large and unusual
outbreak of leishmaniasis in Madrid? Trends Parasitol 2013, 29:579–580.
16. Arce A, Estirado A, Ordobas M, Sevilla S, Garcia N, Moratilla L, de la Fuente S,
Martinez AM, Perez AM, Aranguez E, Iriso A, Sevillano O, Bernal J, Vilas F:
Re-emergence of leishmaniasis in Spain: community outbreak in Madrid,
Spain, 2009 to 2012. Euro Surveill 2013, 18:20546.
17. Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Ferrer L: Canine
leishmaniosis - new concepts and insights on an expanding zoonosis:
part one. Trends Parasitol 2008, 24:324–330.
18. Solano-Gallego L, Koutinas A, Miró G, Cardoso L, Pennisi MG, Ferrer L, Bourdeau
P, Oliva G, Baneth G: Directions for the diagnosis, clinical staging, treatment
and prevention of canine leishmaniosis. Vet Parasitol 2009, 165:1–18.
19. Solano-Gallego L, Miro G, Koutinas A, Cardoso L, Pennisi MG, Ferrer L,
Bourdeau P, Oliva G, Baneth G: LeishVet guidelines for the practical
management of canine leishmaniosis. Parasite Vectors 2011, 4:86.
20. De Tommasi AS, Otranto D, Dantas-Torres F, Capelli G, Breitschwerdt EB,
de Caprariis D: Are vector-borne pathogen co-infections complicating the
clinical presentation in dogs? Parasite Vectors 2013, 6:97.
21. Palacio J, Liste F, Gascon M: Urinary protein/creatinine ratio in the evaluation
of renal failure in canine leishmaniasis. Vet Rec 1995, 137:567–568.
22. Oliva G, Roura X, Crotti A, Maroli M, Castagnaro M, Gradoni L, Lubas G,
Paltrinieri S, Zatelli A, Zini E: Guidelines for treatment of leishmaniasis in
dogs. J Am Vet Med Assoc 2010, 236:1192–1198.
23. Miró G, Cardoso L, Pennisi MG, Oliva G, Baneth G: Canine leishmaniosis–
new concepts and insights on an expanding zoonosis: part two.
Trends Parasitol 2008, 24:371–377.
24. Miró G, Gálvez R, Fraile C, Descalzo MA, Molina R: Infectivity to
Phlebotomus perniciosus of dogs naturally parasitized with Leishmania
infantum after different treatments. Parasite Vectors 2011, 4:52.
25. Ribeiro RR, Moura EP, Pimentel VM, Sampaio WM, Silva SM, Schettini DA,
Alves CF, Melo FA, Tafuri WL, Demicheli C, Melo MN, Frezard F, Michalick
MS: Reduced tissue parasitic load and infectivity to sand flies in dogs
naturally infected by Leishmania (Leishmania) chagasi following
treatment with a liposome formulation of meglumine antimoniate.
Antimicrob Agents Chemother 2008, 52:2564–2572.
26. Manna L, Reale S, Vitale F, Picillo E, Pavone LM, Gravino AE: Real-time PCR
assay in Leishmania-infected dogs treated with meglumine antimoniate
and allopurinol. Vet J 2008, 177:279–282.
27. Denerolle P, Bourdoiseau G: Combination allopurinol and antimony
treatment versus antimony alone and allopurinol alone in the treatment
of canine leishmaniasis (96 cases). J Vet Intern Med 1999, 13:413–415.
28. Miró G, Oliva G, Cruz I, Cañavate C, Mortarino M, Vischer C, Bianciardi P:
Multicentric, controlled clinical study to evaluate effectiveness and
safety of miltefosine and allopurinol for canine leishmaniosis.
Vet Dermatol 2009, 20:397–404.
29. Hernández L, Gálvez R, Montoya A, Checa R, Bello A, Bosschaerts T, Jansen
H, Rupérez C, Fortin A, Miró G: First study on efficacy and tolerability of a
new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the
treatment of canine leishmaniosis due to Leishmania infantum. Parasitol
Res 2014, 113:157–164.30. Gómez-Ochoa P, Castillo JA, Gascón M, Zarate JJ, Alvarez F, Couto CG: Use
of domperidone in the treatment of canine visceral leishmaniasis: a
clinical trial. Vet J 2009, 179:259–263.
31. Foglia Manzillo V, Oliva G, Pagano A, Manna L, Maroli M, Gradoni L:
Deltamethrin-impregnated collars for the control of canine
leishmaniasis: evaluation of the protective effect and influence on
the clinical outcome of Leishmania infection in kennelled stray dogs.
Vet Parasitol 2006, 142:142–145.
32. Otranto D, Paradies P, Lia RP, Latrofa MS, Testini G, Cantacessi C, Mencke N,
Galli G, Capelli G, Stanneck D: Efficacy of a combination of 10%
imidacloprid/50% permethrin for the prevention of leishmaniasis in
kennelled dogs in an endemic area. Vet Parasitol 2007, 144:270–278.
33. Gavgani AS, Hodjati MH, Mohite H, Davies CR: Effect of insecticide-
impregnated dog collars on incidence of zoonotic visceral leishmaniasis
in Iranian children: a matched-cluster randomised trial. Lancet 2002,
360:374–379.
34. Otranto D, Dantas-Torres F, de Caprariis D, Di Paola G, Tarallo VD, Latrofa MS, Lia
RP, Annoscia G, Breitshwerdt EB, Cantacessi C, Capelli G, Stanneck D: Prevention
of canine leishmaniosis in a hyper-endemic area using a combination of 10%
imidacloprid/4.5% flumethrin. PLoS One 2013, 8:e56374.
35. Maroli M, Mizzon V, Siragusa C, D’Oorazi A, Gradoni L: Evidence for an
impact on the incidence of canine leishmaniasis by the mass use of
deltamethrin-impregnated dog collars in southern Italy. Med Vet Entomol
2001, 15:358–363.
36. Otranto D, Dantas-Torres F: The prevention of canine leishmaniasis and its
impact on public health. Trends Parasitol 2013, 29:339–345.
37. Palatnik-de-Sousa CB: Vaccines for leishmaniasis in the fore coming 25
years. Vaccine 2008, 26:1709–1724.
38. Reis AB, Giunchetti RC, Carrillo E, Martins-Filho OA, Moreno J: Immunity
to Leishmania and the rational search for vaccines against canine
leishmaniasis. Trends Parasitol 2010, 26:341–349.
39. Lemesre JL, Holzmuller P, Cavaleyra M, Goncalves RB, Hottin G, Papierok G:
Protection against experimental visceral leishmaniasis infection in dogs
immunized with purified excreted secreted antigens of Leishmania
infantum promastigotes. Vaccine 2005, 23:2825–2840.
40. Bongiorno G, Paparcone R, Foglia Manzillo V, Oliva G, Cuisinier AM, Gradoni L:
Vaccination with LiESP/QA-21 (CaniLeish((R))) reduces the intensity of
infection in Phlebotomus perniciosus fed on Leishmania infantum infected
dogs-A preliminary xenodiagnosis study. Vet Parasitol 2013, 197:691–695.
41. Moreno J, Vouldoukis I, Martin V, McGahie D, Cuisinier AM, Gueguen S:
Use of a LiESP/QA-21 vaccine (CaniLeish) stimulates an appropriate
Th1-dominated cell-mediated immune response in dogs. PLoS Negl Trop
Dis 2012, 6:e1683.
42. Bourdeau P, Groulade P: Résultats d’une enqûete sur la leishmaniose.
Prat Méd Chir Anim Comp 1988, 23:5–10.
43. Alcover MM, Ballart C, Serra T, Castells X, Scalone A, Castillejo S, Riera C,
Tebar S, Gramiccia M, Portus M, Gallego M: Temporal trends in canine
leishmaniosis in the Balearic Islands (Spain): a veterinary questionnaire.
Prospective canine leishmaniosis survey and entomological studies
conducted on the Island of Minorca, 20 years after first data were
obtained. Acta Trop 2013, 128:642–651.
44. Ballart C, Alcover MM, Picado A, Nieto J, Castillejo S, Portus M, Gallego M:
First survey on canine leishmaniasis in a non classical area of the disease
in Spain (Lleida, Catalonia) based on a veterinary questionnaire and a
cross-sectional study. Prev Vet Med 2013, 109:116–127.
45. de Ybañez RR, del Rio L, Martínez-Carrasco C, Segovia M, Cox J, Davies C,
Berriatua E: Questionnaire survey on Canine Leishmaniosis in southeastern
Spain. Vet Parasitol 2009, 164:124–133.
46. Galvez R, Miro G, Descalzo MA, Molina R: Questionnaire-based survey on
the clinical management of canine leishmaniosis in the Madrid region
(central Spain). Prev Vet Med 2011, 102:59–65.
47. Schmidt PL: Evidence-based veterinary medicine: evolution, revolution,
or repackaging of veterinary practice? Vet Clin North Am Small Anim Pract
2007, 37:409–417.
48. Mencke N: The importance of canine leishmaniosis in non-endemic
areas, with special emphasis on the situation in Germany. Berl Munch
Tierarztl Wochenschr 2011, 124:434–442.
49. Paltrinieri S, Solano-Gallego L, Fondati A, Lubas G, Gradoni L, Castagnaro M,
Crotti A, Maroli M, Oliva G, Roura X, Zatelli A, Zini E: Guidelines for
diagnosis and clinical classification of leishmaniasis in dogs. J Am Vet
Med Assoc 2010, 236:1184–1191.
Bourdeau et al. Parasites & Vectors 2014, 7:110 Page 14 of 14
http://www.parasitesandvectors.com/content/7/1/11050. Ciaramella P, Oliva G, Luna RD, Gradoni L, Ambrosio R, Cortese L, Scalone A,
Persechino A: A retrospective clinical study of canine leishmaniasis in 150
dogs naturally infected by Leishmania infantum. Vet Rec 1997, 141:539–543.
51. Dos-Santos WL, Jesus EE, Paranhos-Silva M, Pereira AM, Santos JC, Baleeiro
CO, Nascimento EG, Moreira ED, Oliveira GG, Pontes-de-Carvalho LC:
Associations among immunological, parasitological and clinical
parameters in canine visceral leishmaniasis: Emaciation, spleen
parasitism, specific antibodies and leishmanin skin test reaction.
Vet Immunol Immunopathol 2008, 123:251–259.
52. Lima WG, Michalick MS, de Melo MN, Luiz Tafuri W, Luiz Tafuri W: Canine
visceral leishmaniasis: a histopathological study of lymph nodes.
Acta Trop 2004, 92:43–53.
53. Mylonakis ME, Papaioannou N, Saridomichelakis MN, Koutinas AF, Billinis C,
Kontos VI: Cytologic patterns of lymphadenopathy in dogs infected with
Leishmania infantum. Vet Clin Pathol 2005, 34:243–247.
54. Ciaramella P, Pelagalli A, Cortese L, Pero ME, Corona M, Lombardi P,
Avallone L, Persechino A: Altered platelet aggregation and coagulation
disorders related to clinical findings in 30 dogs naturally infected by
Leishmania infantum. Vet J 2005, 169:465–467.
55. Koutinas AF, Polizopoulou ZS, Saridomichelakis MN, Argyriadis D, Fytianou
A, Plevraki KG: Clinical considerations on canine visceral leishmaniasis in
Greece: a retrospective study of 158 cases (1989–1996). J Am Anim Hosp
Assoc 1999, 35:376–383.
56. Plevraki K, Koutinas AF, Kaldrymidou H, Roumpies N, Papazoglou LG,
Saridomichelakis MN, Savvas I, Leondides L: Effects of allopurinol
treatment on the progression of chronic nephritis in Canine
leishmaniosis (Leishmania infantum). J Vet Intern Med 2006, 20:228–233.
57. Wolschrijn CF, Meyer HP, Hazewinkel HA, Wolvekamp WT: Destructive
polyarthritis in a dog with leishmaniasis. J Small Anim Pract 1996, 37:601–603.
58. Naranjo C, Fondevila D, Leiva M, Roura X, Peña T: Characterization of lacrimal
gland lesions and possible pathogenic mechanisms of keratoconjunctivitis
sicca in dogs with leishmaniosis. Vet Parasitol 2005, 133:37–47.
59. Peña MT, Naranjo C, Klauss G, Fondevila D, Leiva M, Roura X, Davidson MG,
Dubielzig RR: Histopathological features of ocular leishmaniosis in the
dog. J Comp Pathol 2008, 138:32–39.
60. Peña MT, Roura X, Davidson MG: Ocular and periocular manifestations of
leishmaniasis in dogs: 105 cases (1993–1998). Vet Ophthalmol 2000, 3:35–41.
61. Petanides TA, Koutinas AF, Mylonakis ME, Day MJ, Saridomichelakis MN,
Leontides LS, Mischke R, Diniz P, Breitschwerdt EB, Kritsepi M, Garipidou VA,
Koutinas CK, Lekkas S: Factors associated with the occurrence of epistaxis
in natural canine leishmaniasis (Leishmania infantum). J Vet Intern Med
2008, 22:866–872.
62. Costa FA, Goto H, Saldanha LC, Silva SM, Sinhorini IL, Silva TC, Guerra JL:
Histopathologic patterns of nephropathy in naturally acquired canine
visceral leishmaniasis. Vet Pathol 2003, 40:677–684.
63. Adamama-Moraitou KK, Rallis TS, Koytinas AF, Tontis D, Plevraki K, Kritsepi M:
Asymptomatic colitis in naturally infected dogs with Leishmania
infantum: a prospective study. Am J Trop Med Hyg 2007, 76:53–57.
64. Ferrer L, Juanola B, Ramos JA, Ramis A: Chronic colitis due to Leishmania
infection in two dogs. Vet Pathol 1991, 28:342–343.
65. Cortese L, Pelagalli A, Piantedosi D, Mastellone V, Manco A, Lombardi P,
Ciaramella P, Avallone L: Platelet aggregation and haemostatic response
in dogs naturally co-infected by Leishmania infantum and Ehrlichia
canis. J Vet Med A Physiol Pathol Clin Med 2006, 53:546–548.
66. Foglia Manzillo V, Pagano A, Guglielmino R, Gradoni L, Restucci B, Oliva G:
Extranodal gammadelta-T-cell lymphoma in a dog with leishmaniasis.
Vet Clin Pathol 2008, 37:298–301.
67. Mozos E, Perez J, Day MJ, Lucena R, Ginel PJ: Leishmaniosis and
generalized demodicosis in three dogs: a clinicopathological and
immunohistochemical study. J Comp Pathol 1999, 120:257–268.
68. Irwin PJ: It shouldn’t happen to a dog … or a veterinarian: clinical
paradigms for canine vector-borne diseases. Trends Parasitol 2014,
30:104–112.
69. Saridomichelakis MN, Mylonakis ME, Leontides LS, Koutinas AF, Billinis C,
Kontos VI: Evaluation of lymph node and bone marrow cytology in the
diagnosis of canine leishmaniasis (Leishmania infantum) in symptomatic
and asymptomatic dogs. Am J Trop Med Hyg 2005, 73:82–86.
70. Francino O, Altet L, Sánchez-Robert E, Rodríguez A, Solano-Gallego L,
Alberola J, Ferrer L, Sánchez A, Roura X: Advantages of real-time PCR assay
for diagnosis and monitoring of canine leishmaniosis. Vet Parasitol 2006,
137:214–221.71. Martinez V, Quilez J, Sanchez A, Roura X, Francino O, Altet L: Canine
leishmaniasis: the key points for qPCR result interpretation. Parasite
Vectors 2011, 4:57.
72. Palacio J, Liste F, Gascon M: Enzymuria as an index of renal damage in
canine leishmaniasis. Vet Rec 1997, 140:477–480.
73. Noli C, Auxilia ST: Treatment of canine Old World visceral leishmaniasis:
a systematic review. Vet Dermatol 2005, 16:213–232.
74. Zaghloul IY, Al-Jasser M: Effect of renal impairment on the pharmacokin-
etics of antimony in hamsters. Ann Trop Med Parasitol 2004, 98:793–800.
75. Torres M, Bardagi M, Roura X, Zanna G, Ravera I, Ferrer L: Long term follow-
up of dogs diagnosed with leishmaniosis (clinical stage II) and treated
with meglumine antimoniate and allopurinol. Vet J 2011, 188:346–351.
76. Ikeda-Garcia FA, Lopes RS, Ciarlini PC, Marques FJ, Lima VM, Perri SH, Feitosa
MM: Evaluation of renal and hepatic functions in dogs naturally infected
by visceral leishmaniasis submitted to treatment with meglumine
antimoniate. Res Vet Sci 2007, 83:105–108.
77. Morosetti G, Bongiorno G, Beran B, Scalone A, Moser J, Gramiccia M,
Gradoni L, Maroli M: Risk assessment for canine leishmaniasis spreading
in the north of Italy. Geospat Health 2009, 4:115–127.
78. Podaliri Vulpiani M, Iannetti L, Di Mattia T, Dalla Villa P: Leishmania
infantum in a Central Italy dog shelter: Retrospective study of serologic
reactivity during a 4-year period in a confined dog population subjected
to preventive and therapeutic treatment. Vet Parasitol 2009, 160:190–197.
79. Gálvez R, Miró G, Descalzo MA, Nieto J, Dado D, Martín O, Cubero E, Molina
R: Emerging trends in the seroprevalence of canine leishmaniosis in the
Madrid region (central Spain). Vet Parasitol 2010, 169:327–334.
80. Martín-Sánchez J, Morales-Yuste M, Acedo-Sánchez C, Barón S, Díaz V,
Morillas-Márquez F: Canine leishmaniasis in southeastern Spain.
Emerg Infect Dis 2009, 15:795–798.
81. Bray DP, Hamilton JG: Insecticide-impregnated netting as a potential tool
for long-lasting control of the leishmaniasis vector Lutzomyia longipalpis
in animal shelters. Parasite Vectors 2013, 6:133.
doi:10.1186/1756-3305-7-110
Cite this article as: Bourdeau et al.: Management of canine leishmaniosis
in endemic SW European regions: a questionnaire-based multinational
survey. Parasites & Vectors 2014 7:110.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
